Breaking News Instant updates and real-time market news.

WDAY

Workday

, MRK

Merck

09:41
01/11/17
01/11
09:41
01/11/17
09:41

Unusually active option classes on open January 11th

Unusual total active option classes on open include: Workday (WDAY), Merck (MRK), Mondelez (MDLZ), Activision Blizzard (ATVI), Bristol Myers Squibb (BMY), Salesforce (CRM), GDXJ (GDXJ), American Airlines (AAL), Rite Aid (RAD), and GDM (GDX).

WDAY

Workday

MRK

Merck

MDLZ

Mondelez

$44.17

-0.52 (-1.16%)

ATVI

Activision Blizzard

$38.38

0.68 (1.80%)

BMY

Bristol-Myers

CRM

Salesforce

AAL

American Airlines

$48.48

1.4 (2.97%)

RAD

Rite Aid

GDX

Market Vector Gold Miners

  • 11

    Jan

  • 11

    Jan

  • 11

    Jan

  • 12

    Jan

  • 12

    Jan

  • 18

    Jan

  • 19

    Jan

  • 19

    Jan

  • 26

    Jan

  • 01

    Feb

  • 02

    Feb

  • 20

    Feb

  • 21

    Feb

  • 28

    Feb

  • 08

    Mar

  • 27

    May

WDAY Workday

01/11/17
WBLR
01/11/17
NO CHANGE
WBLR
Outperform
Blair uncovers Workday deal with one of world's largest employers
William Blair analyst Justin Furby says he learned from Workday (WDAY) partners that the company recently signed a human resources deal with one of the world's largest employers. The contract, with a retailer employing over 2M people globally, represents the largest company Workday has ever signed "by far," Furby tells investors in a research note. The client is more than five times larger on a headcount basis than any of Workday's existing HR customers, the analyst adds. The company competed against incumbent SAP (SAP), and the retailer will pursue a phased deployment over the next three to four years, Furbry says. He believes a deal of this size could represent $30M or more of annual subscription revenue. Furby also learned of a 70,000-plus employee real estate firm and a 50,000-plus employee pharmaceutical firm that recently closed with Workday, as well as "several large enterprise opportunities" in pipeline that could close in the coming weeks. Workday shares remain one of the analyst's favorite ideas this year and over the longer term, and he recommends using current levels as a long-term buying opportunity. Furby has an Outperform rating on Workday, which is up 72c to $75.07 in pre-market trading.
01/10/17
WELS
01/10/17
INITIATION
WELS
Market Perform
Workday initiated with a Market Perform at Wells Fargo
Wells Fargo analyst Philip Winslow started Workday with a Market Perform rating and $75-$80 price target range.
01/06/17
WEDB
01/06/17
NO CHANGE
WEDB
Wedbush more positive on 2017 software spending trends
Wedbush analyst Steve Koenig says his firm's 2017 IT Spending Survey should soothe fears that macro uncertainty caused by the U.S. presidential election will negatively impact IT budgets. The analyst thinks recent disappointments from Workday (WDAY), Oracle (ORCL), Red Hat (RHT), and other software vendors were more company-specific than the management teams were willing to admit. As a result of the survey, Koenig has a more positive view of 2017 software spending trends, and thinks beneficiaries will include well-positioned cybersecurity vendors and cloud vendors. He notes that Proofpoint (PFPT) is a Wedbush Best Idea and his top software pick for 2017 along with salesforce.com (CRM).
12/07/16
NORL
12/07/16
DOWNGRADE
NORL
Market Perform
Workday downgraded to Market Perform from Outperform at Northland
MRK Merck

01/11/17
JPMS
01/11/17
NO CHANGE
JPMS
Overweight
Keytruda filing a 'distinct positive' for Merck, says JPMorgan
JPMorgan analyst Chris Schott views the acceptance of the Keytruda plus chemo combo supplementary Biologics License Application for priority review as a "distinct positive" for Merck (MRK). The company is increasingly well positioned in first-line lung cancer, Schott tells investors in a research note. The analyst reiterates an Overweight rating on Merck.
01/11/17
JEFF
01/11/17
NO CHANGE
Target $48
JEFF
Buy
Merck filing for Keytruda could disrupt market, says Jefferies
Jefferies analyst Jeffrey Holford views Merck's (MRK) filing for Keytruda plus chemo in first line non-small cell lung cancer as a "positive surprise" that could disrupt market share dynamics in the near term, particularly for Bristol-Myers (BMY). The filing, however, does not materially change Merck's long term outlook, Holford tells investors in a research note. He believes approval risk is high given limited data and keeps an Underperform rating on Merck. The stock is up $1.78 to $61.70 in pre-market trading while Bristol-Myers is down $1.98 to $58.00.
01/11/17
BMOC
01/11/17
NO CHANGE
BMOC
FDA decision a significant boost for Merck, says BMO Capital
BMO Capital analyst Alex Arfaei says that the FDA's acceptance and priority review of Merck's Keytruda+chemo in first line non-small cell lung cancer "is a positive surprise." and "represents significant upside" for the company. The analyst thinks that Keytruda's market share in first line non-small cell lung cancer can reach about 80%-85%, up from about 25% now. He continues to identify Merck as his top pick.
01/11/17
GSCO
01/11/17
NO CHANGE
Target $70
GSCO
Neutral
Goldman sees Merck advantage for Keytruda in first-line NSCLC to be short-lived
Goldman Sachs analyst Jami Rubin said that if Merck's (MRK) chemo combo sBLA is approved, she would expect a "rapid uptake" for Keytruda in the first-line setting given there will be no requirement for PD-L1 testing. However, while Merck may benefit in the near-term in 2017, she is making no change to her 2018 estimates given imminent competition from potentially three other players, adding that she is also making no changes to her estimates for Bristol-Myers (BMY) as she has estimates for first-line non-small cell lung cancer only from 2018. Rubin maintains her Neutral rating and $70 price target on Merck shares.
MDLZ Mondelez
$44.17

-0.52 (-1.16%)

01/05/17
01/05/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Adobe (ADBE) was initiated with an Outperform and FireEye (FEYE) was initiated with a Market Perform at BMO Capital. 2. Hilton (HLT) initiated with a Buy at Goldman and a Sell at Berenberg. 3. Hershey (HSY) initiated with a Sell at Berenberg. 4. PayPal (PYPL) initiated with a Buy at Guggenheim. 5. Mondelez (MDLZ) initiated with a Buy at Berenberg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/10/16
11/10/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. BHP Billiton (BHP) initiated with a Hold at HSBC. 2. Mondelez (MDLZ) reinstated with a Hold at Deutsche Bank. 3. Yum China (YUMC) initiated with an Outperform at Oppenheimer. 4. Arch Coal (ARCH) initiated with a Buy at Seaport Global. 5. Zions Bancorp (ZIOP) coverage assumed with an Outperform at RBC Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/15/16
JPMS
12/15/16
NO CHANGE
JPMS
JPMorgan weighs in on Swiss-based Kraft for Mondelez story
Is the Swiss-based magazine Bilanz's article that Kraft Heinz (KHC) is looking to buy Mondelez (MDLZ) legitimate? "Frankly, we do not know," JPMorgan analyst Ken Goldman tells investors in a research note. The analyst until yesterday had never heard of Bilanz. Goldman points out Bloomberg last night reported that Kraft Heinz is not currently in talks to acquire Mondelez, according to people familiar with the matter. Nonetheless, Goldman provided a hypothetical Kraft/Mondelez accretion model for investors. Assuming a 25% takeout premium on Mondelez's closing price of $42.83, the analyst estimates 25% deal accretion for Kraft. In pre-market trading, Mondelez is up $2.07, or 5%, to $44.90 while Kraft Heinz is up 2% to $85.75.
01/05/17
BREN
01/05/17
INITIATION
Target $51.15
BREN
Buy
Mondelez initiated with a Buy at Berenberg
Berneberg analyst Fintan Ryan initiated Mondelez with a Buy and a $51.15 price target based on expectations of accelerating organic sales and EBIT growth by more effectively leveraging its global brand portfolio. He expects continued margin and cash flow improvement from supply chain and overhead cost savings will drive best in group earnings CAGR.
ATVI Activision Blizzard
$38.38

0.68 (1.80%)

12/09/16
PIPR
12/09/16
NO CHANGE
PIPR
November NPD video game software sales dropped 22%, says Piper Jaffray
Piper Jaffray analyst Michael Olson says November NPD video game software sales were down 22% year-over-year due to a difficult compare with launches last year of Call of Duty: Black Ops III from Activision (ATVI) and Fallout 4 from Bethesda. This year's Call of Duty: Infinite Warfare was among the top titles for the month but "down significantly" relative to the prior iteration, Olson tells investors in a research note. Other top titles for this November included Electronic Arts' (EA) Battlefield 1 and Titanfall 2, as well as Nintendo's (NTODY) pair of 3DS Pokemon titles Sun and Moon, the analyst points out. He maintains Overweight ratings on Activision, Electronic Arts and Take-Two (TTWO) and a Neutral rating on GameStop (GME).
12/08/16
BARD
12/08/16
NO CHANGE
Target $47
BARD
Outperform
Activision Blizzard weakness would be buying opportunity, says Baird
Baird analyst Colin Sebastian lowered his estimates on Activision Blizzard to reflect holiday field checks, which show improving retail sales for Call of Duty at discount prices but not enough to fill the Q4 gap. The shortfall will be partially made up by digital and micro-transactions, but this could lead to a potential negative carry-over for 2017 guidance, said Sebastian, who maintained his Outperform rating and lowered his price target to $47 from $50 on Activision Blizzard shares.
11/11/16
PIPR
11/11/16
NO CHANGE
PIPR
Oct. NPD video game software sales rose 11%, says Piper Jaffray
Piper Jaffray analyst Michael Olson says October NPD video game software sales were up 11% year-over-year due to strong results from incremental launch titles, including Electronic Arts' (EA) Battlefield 1 as well as Take Two's (TTWO) Mafia III, among others. The analyst, however, views the October NPD results as "largely irrelevant" since Activision Blizzard (ATVI), EA and Take-Two already announced December quarter guidance and GameStop (GME) recently announced preliminary October quarter results. He keeps Overweight ratings on all four names.
11/30/16
JEFF
11/30/16
NO CHANGE
Target $55
JEFF
Buy
Activision Call of Duty price mix should offset unit declines, says Jefferies
Jefferies analyst Brian Fitzgerald attributes the 17% pullback in Activision Blizzard (ATVI) from its 52-week high in October to fears that Call of Duty is underperforming. He points to the game underperforming at GameStop (GME) and the fact that Activision did not issue a post-launch press release around COD performance for the first time since 2008 as potential signs of softness. However, Fitzgerald thinks the unit declines may be partially offset by higher uptake of the $80 premium version of the game and notes that Overwatch and WoW have both had engagement spikes. The analyst expressed confidence in his 2017 EPS estimates for Activision and maintains his Buy rating and $55 price target on the stock.
BMY Bristol-Myers

12/19/16
JEFF
12/19/16
DOWNGRADE
Target $48
JEFF
Underperform
Merck downgraded to Underperform from Hold at Jefferies
Jefferies analyst Jeffrey Holford downgraded Merck (MRK) to Underperform, his firm's sell-rating equivalent. The analyst sees Pharmaceutical sector fundamentals weakening in 2017 amid political overhangs and an adverse macro environment. Potential dual eligible rebate reform is the most significant risk, Holford tells investors in a research note. Specific to Merck, the analyst expects further pressure on Keytruda in 2018, driven by share losses in non-small cell lung cancer to Bristol-Myers Squibb (BMY), AstraZeneca (AZN) and Roche (RHHBY). Merck screens poorly on many valuation metrics, Holford contends. He lowered his price target for the shares to $48 from $59. The stock closed Friday up 7c to $62.44. The analyst this morning also upgraded both Bristol-Myers Squibb (BMY) and Bayer (BAYRY) to Buy from Hold. His top picks in Pharmaceuticals are AbbVie (ABBV) and Eli Lilly (LLY) for the U.S. and AstraZeneca and Novartis (NVS) in Europe.
12/19/16
12/19/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bristol-Myers (BMY) and Bayer (BAYRY) were upgraded to Buy from Hold at Jefferies. 2. Costco (COST) upgraded to Buy from Neutral at Citi with analyst Kate McShane saying she sees a "clear path" to accelerating same-store-sales growth in fiscal 2017 as gasoline price deflation headwinds abate and benefits arise from the new co-branded credit card. 3. United Technologies (UTX) upgraded to Outperform from Neutral at Credit Suisse with analyst Julian Mitchell saying he believes consensus estimates are poised to move higher after years of heavy investment spending drive an earnings recovery. 4. ASML (ASML) upgraded to Buy from Neutral at BofA/Merrill with analyst Kai Korschelt saying a recent expert's call indicates progress with Extreme Ultraviolet/EUV lightsource optics & ecosystem and sees improving volume visibility from 2018 forward. 5. Gulfport Energy (GPOR) upgraded to Buy from Neutral at Guggenheim and to Overweight from Equal Weight at Stephens. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CRM Salesforce

01/05/17
01/05/17
NO CHANGE

Pacific Crest names top cloud stocks for 2017
Pacific Crest analyst Brent Bracelin remains upbeat on cloud application pure plays, citing his belief that public cloud spending is poised to triple by 2020. He identifies the following cloud application software stocks as having the best risk/reward ratio and the best chances of success: Microsoft (MSFT), Adobe (ADBE), Salesforce (CRM), Veeva (VEEV), Ellie Mae (ELLI), Twilio (TWLO), and HubSpot (HUBS).
01/09/17
UBSW
01/09/17
NO CHANGE
Target $105
UBSW
Buy
Salesforce could be top turnaround story of 2017, says UBS
UBS analyst Brent Thill noted Salesforce was one of the worst performing large cap software stocks of 2017 and said it could be the top turnaround story of 2017 with the right management actions.He believes management should address M&A concerns by taking any potential mega-deals off the table and focus on re-accelerating organic growth, especially in the Marketing Cloud. Thill reiterated his Buy rating and $105 price target on Salesforce shares.
01/10/17
WELS
01/10/17
INITIATION
WELS
Outperform
Salesforce initiated with an Outperform at Wells Fargo
Wells Fargo analyst Philip Winslow started Salesforce with an Outperform rating and $100-$105 price target range.
AAL American Airlines
$48.48

1.4 (2.97%)

12/15/16
LEHM
12/15/16
INITIATION
Target $62
LEHM
Equal Weight
American Airlines initiated with an Equal Weight at Barclays
Barclays analyst Brandon Oglenski started American Airlines with an Equal Weight rating and $62 price target.
01/04/17
COWN
01/04/17
DOWNGRADE
Target $50
COWN
Market Perform
American Airlines downgraded to Market Perform from Outperform at Cowen
Cowen analyst Helane Becker downgraded American Airlines to Market Perform from Outperform based on valuation. Becker reiterated her $50 price target on American Airlines shares.
01/04/17
01/04/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. JPMorgan analyst Richard Vosser downgraded Novartis (NVS) to Neutral from Overweight saying pressures on the company's business are mounting. The pressure from generic erosion in 2017 "remains high" with an estimated $2.3B of sales expected to be lost to generics, said Vosser, who sees "significant downside" to consensus estimates for Novartis. 2. BofA Merrill Lynch analyst Lisa Lewandowski downgraded Philip Morris (PM) to Neutral from Buy and lowered its price target to $96 from $102 citing concerns from the strong U.S. dollar, less impact from an overhaul in U.S. tax policy versus peers, underperformance in combustible tobacco volumes, increasing heat-not-burn competition, a rotation out of defensive/bond proxy assets, and debt convent constraints. 3. Jefferies analyst Andy Barish downgraded Dunkin' Brands (DNKN) to Underperform from Hold, saying he does not believe the company's same-store-sales have broken out above 2% while its international growth has been disappointing. Barish also downgraded Cheesecake Factory (CAKE) to Underperform, citing the 15% post-election rally with no change in fundamentals along with the company's "significant" mall exposure. 4. Evercore ISI downgraded Intuitive Surgical (ISRG) to Hold from Buy and lowered its price target to $690 from $780, with analyst Vijay Kumar saying he expects 2017 to be one of the most challenging for healthcare in general, with the sector facing issues ranging from ACA repeal to border tax reform to interest expense deductibility. 5. Cowen analyst Helane Becker downgraded a number of airline stocks, including United Continental (UAL), JetBlue (JBLU), Alaska Air (ALK) and American Airlines (AAL), to Market Perform from Outperform based on valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/18/16
11/18/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cisco (CSCO) coverage resumed with a Hold at Stifel. 2. UPS (UPS) was initiated with an Outperform at BMO Capital while the firm initiated FedEx (FDX) with a Market Perform. 3. Synchrony (SYF) was initiated with an Overweight at Stephens. The firm also initiated American Express (AXP) and Discover (DFS) with an Underweight. 4. American Airlines (AAL), Delta Air Lines (DAL), Southwest (LUV) and Allegiant Travel (ALGT) were initiated with a Buy at Citi while the firm initiated JetBlue (JBLU), United Continental (UAL), Alaska Air (ALK), and Hawaiian Holdings (HA) with a Neutral. 5. Juniper (JNPR) coverage resumed at Stifel. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
RAD Rite Aid

12/20/16
EVER
12/20/16
NO CHANGE
EVER
Cardinal Health likely to benefit from Fred's asset acquisition, says Evercore ISI
Evercore ISI analyst Ross Muken said Cardinal Health (CAH) is likely to benefit from Fred's (FRED) acquisition of 865 stores from Walgreens Boots (WAG)/Rite Aid (RAD) as it is Fred's current distributor.
01/06/17
01/06/17
UPGRADE
Target $17.5

Equal Weight
Fred's upgraded to Equal Weight after Rite Aid pact at Stephens
As previously reported, Stephens analyst Ben Bienvenu upgraded Fred's (FRED) to Equal Weight from Underweight citing the company's agreement to purchase 865 Rite Aid (RAD) stores from Walgreens (WBA), which he acknowledged "could be transformational longer term" if approved by the FTC. However, he also thinks the execution risk is very high in the near-term and notes that the retail pharmacy and discount retail industries are currently very competitive. Bienvenu raised his price target on Fred's shares to $17.50 from $7.
01/06/17
LEER
01/06/17
NO CHANGE
Target $90
LEER
Outperform
Leerink 'slightly more cautious' on Walgreens Boots Alliance after results
Leerink analyst David Larsen says he is "slightly more cautious" on shares of Walgreens Boots Alliance (WBA) following Q1 results. Nonetheless, the analyst reiterates an Outperform rating and $90 price target on the shares, mainly due to the fact that all of the new volumes from recent deals will start flowing through to Walgreens Boots Alliance next quarter and as he thinks that there may be a modest rally in Walgreens Boots Alliance if and when the Rite Aid (RAD) deal actually closes given the latter's stock price.
11/15/16
LEER
11/15/16
NO CHANGE
Target $85
LEER
Outperform
CVS Health price target lowered to $85 from $105 at Leerink
Leerink analyst David Larsen lowered his price target for CVS Health (CVS) to $85 from $105 as he is incrementally more cautious on the company. Conversely, the analyst is incrementally more positive on Walgreens Boots Alliance (WBA) and believes its deal with Rite Aid (RAD) deal is more likely to go through with Trump as President. Nonetheless, Larsen believes that 2017 is largely a re-set year for CVS Health, and expects the business to return to more robust growth in 2018 and beyond. He reiterates an Outperform rating on CVS Health's shares.
GDX Market Vector Gold Miners

TODAY'S FREE FLY STORIES

KFY

Korn/Ferry

$31.27

0.42 (1.36%)

20:27
03/28/17
03/28
20:27
03/28/17
20:27
Conference/Events
Korn/Ferry management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 30

    Mar

EEFT

Euronet

$84.38

0.57 (0.68%)

20:25
03/28/17
03/28
20:25
03/28/17
20:25
Conference/Events
Euronet management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

PAYX

Paychex

$60.58

-0.31 (-0.51%)

, UNF

UniFirst

$136.05

0.65 (0.48%)

20:25
03/28/17
03/28
20:25
03/28/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PAYX

Paychex

$60.58

-0.31 (-0.51%)

UNF

UniFirst

$136.05

0.65 (0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 12

    Apr

MGI

MoneyGram

$16.98

0.23 (1.37%)

, EEFT

Euronet

$84.38

0.57 (0.68%)

20:05
03/28/17
03/28
20:05
03/28/17
20:05
Periodicals
Euronet urges U.S. scrutiny of MoneyGram-Ant Financial deal, Reuters says »

Euronet (EEFT) has issued…

MGI

MoneyGram

$16.98

0.23 (1.37%)

EEFT

Euronet

$84.38

0.57 (0.68%)

BABA

Alibaba

$107.80

-0.28 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

PPG

PPG

$104.97

1.15 (1.11%)

, AKZOY

AkzoNobel

$28.04

-0.34 (-1.20%)

20:02
03/28/17
03/28
20:02
03/28/17
20:02
Periodicals
AkzoNobel holders push for talks with PPG, FT says »

Investors holding nearly…

PPG

PPG

$104.97

1.15 (1.11%)

AKZOY

AkzoNobel

$28.04

-0.34 (-1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

19:58
03/28/17
03/28
19:58
03/28/17
19:58
Periodicals
Trump to be briefed Thursday on tax overhaul options, Bloomberg says »

President Donald Trump…

F

Ford

$11.65

0.19 (1.66%)

19:45
03/28/17
03/28
19:45
03/28/17
19:45
Conference/Events
Ford management to meet with JPMorgan »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 28

    Mar

  • 03

    Apr

  • 27

    Apr

VZ

Verizon

$49.30

0.16 (0.33%)

, CMCSA

Comcast

$37.09

-0.02 (-0.05%)

19:26
03/28/17
03/28
19:26
03/28/17
19:26
Hot Stocks
House joins Senate in passing roll-back of ISP data privacy rules »

Resolution S.J. 34 has…

VZ

Verizon

$49.30

0.16 (0.33%)

CMCSA

Comcast

$37.09

-0.02 (-0.05%)

CMCSK

Comcast

T

AT&T

$41.56

0.07 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 09

    May

TSLA

Tesla

$277.45

7.23 (2.68%)

19:09
03/28/17
03/28
19:09
03/28/17
19:09
Periodicals
Tesla allegedly in Autopilot mode bumps police motorcycle, azcentral says »

A Tesla Model X had a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

TRP

TransCanada

$46.57

-0.07 (-0.15%)

19:05
03/28/17
03/28
19:05
03/28/17
19:05
Periodicals
TransCanada COO Alex Pourbaix to retire in May, Reuters reports »

TransCanada COO Alex…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSBC

HSBC

$41.05

0.36 (0.88%)

19:03
03/28/17
03/28
19:03
03/28/17
19:03
Periodicals
HSBC weighs raising as much as $1B for private credit fund, Bloomberg says »

HSBC's asset…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Apr

AMZN

Amazon.com

$856.00

9.18 (1.08%)

, EBAY

eBay

$33.53

0.1 (0.30%)

18:55
03/28/17
03/28
18:55
03/28/17
18:55
Hot Stocks
Barclays initiates key Internet names, sets $1,120 target on Amazon »

Barclays initiated…

AMZN

Amazon.com

$856.00

9.18 (1.08%)

EBAY

eBay

$33.53

0.1 (0.30%)

MELI

MercadoLibre

$211.51

-0.06 (-0.03%)

GOOG

Alphabet

$820.92

1.41 (0.17%)

GOOGL

Alphabet Class A

$840.63

2.12 (0.25%)

FB

Facebook

$141.76

1.44 (1.03%)

SNAP

Snap

$22.21

-1.62 (-6.80%)

TWTR

Twitter

$14.94

-0.05 (-0.33%)

GRPN

Groupon

$3.96

0.01 (0.25%)

GDDY

GoDaddy

$36.30

-0.16 (-0.44%)

SHOP

Shopify

$72.37

1.97 (2.80%)

WIX

Wix.com

$66.30

0.15 (0.23%)

WEB

Web.com

$19.30

0.15 (0.78%)

TCEHY

Tencent

$29.49

0.42 (1.44%)

BABA

Alibaba

$107.80

-0.28 (-0.26%)

BIDU

Baidu

$169.79

0.86 (0.51%)

WB

Weibo

$51.61

0.72 (1.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 28

    Mar

  • 28

    Mar

  • 30

    Mar

  • 18

    Apr

  • 02

    May

  • 16

    May

  • 22

    May

  • 24

    May

VRTX

Vertex

$89.67

-1.13 (-1.24%)

18:46
03/28/17
03/28
18:46
03/28/17
18:46
Hot Stocks
Vertex up 21% after two cystic fibrosis studies show significant improvements »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$11.65

0.19 (1.66%)

18:46
03/28/17
03/28
18:46
03/28/17
18:46
Hot Stocks
Ford executive chairman acquires 171,379 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 28

    Mar

  • 03

    Apr

  • 27

    Apr

RTTR

Ritter Pharmaceuticals

$1.95

-0.01 (-0.51%)

18:35
03/28/17
03/28
18:35
03/28/17
18:35
Hot Stocks
Ritter Pharmaceuticals: RP-G28 shows 'clinically meaningful benefit' in study »

Ritter Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLK

BlackRock

$380.63

5.63 (1.50%)

18:31
03/28/17
03/28
18:31
03/28/17
18:31
Hot Stocks
BlackRock to reposition equity investment platform »

BlackRock is positioning…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 12

    Apr

VRTX

Vertex

$89.67

-1.13 (-1.24%)

18:26
03/28/17
03/28
18:26
03/28/17
18:26
Hot Stocks
Vertex says two cystic fibrosis studies show significant improvements »

Vertex Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LITE

Lumentum

$54.70

0.55 (1.02%)

, VIAV

Viavi

$10.83

-0.06 (-0.55%)

18:04
03/28/17
03/28
18:04
03/28/17
18:04
Hot Stocks
AlphaOne's Dan Niles says Lumentum and Viavi are 'under the radar stocks' »

AlphaOne's Dan Niles…

LITE

Lumentum

$54.70

0.55 (1.02%)

VIAV

Viavi

$10.83

-0.06 (-0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMST

HomeStreet

$26.70

0.2 (0.75%)

18:01
03/28/17
03/28
18:01
03/28/17
18:01
Hot Stocks
HomeStreet CFO Bartels to leave company effective April 23 »

HomeStreet, the parent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

CKH

Seacor

$67.35

1.83 (2.79%)

18:00
03/28/17
03/28
18:00
03/28/17
18:00
Earnings
Seacor reports Q4 EPS ($3.36), may not compare with consensus (41c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTX

Pernix Therapeutics

$4.06

-0.11 (-2.64%)

, GSK

GlaxoSmithKline

$42.41

-0.28 (-0.66%)

17:59
03/28/17
03/28
17:59
03/28/17
17:59
Hot Stocks
Pernix says continues to assess various alternatives, including M&A »

"We were pleased to…

PTX

Pernix Therapeutics

$4.06

-0.11 (-2.64%)

GSK

GlaxoSmithKline

$42.41

-0.28 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 06

    Jun

CSC

CSC

$69.07

1.02 (1.50%)

, SWN

Southwestern Energy

$7.89

0.19 (2.47%)

17:57
03/28/17
03/28
17:57
03/28/17
17:57
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P 500 indices »

S&P MidCap 400…

CSC

CSC

$69.07

1.02 (1.50%)

SWN

Southwestern Energy

$7.89

0.19 (2.47%)

HPE

HP Enterprise

$23.01

0.29 (1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 29

    Mar

  • 29

    Mar

  • 06

    Apr

  • 11

    Apr

  • 12

    Apr

  • 13

    Apr

  • 02

    May

  • 12

    Jun

GM

General Motors

$35.56

0.85 (2.45%)

17:52
03/28/17
03/28
17:52
03/28/17
17:52
Earnings
General Motors backs FY17 EPS view $6.00-$6.50, consensus $6.13 »

The company continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLR

Continental Resources

$43.39

0.75 (1.76%)

17:47
03/28/17
03/28
17:47
03/28/17
17:47
Hot Stocks
Continental Resources CEO acquires 41,998 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNET

RigNet

$19.70

-0.2 (-1.01%)

17:39
03/28/17
03/28
17:39
03/28/17
17:39
Hot Stocks
RigNet to provide 4G broadband in Gulf of Mexico deep waters »

RigNet continues its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.